BRIVLERA

This brand name is authorized in Brazil, Canada

Active ingredients

The drug BRIVLERA contains one active pharmaceutical ingredient (API):

1 Brivaracetam UNII U863JGG2IA - BRIVARACETAM

Brivaracetam displays a high and selective affinity for synaptic vesicle protein 2A (SV2A), a transmembrane glycoprotein found at presynaptic level in neurons and in endocrine cells. Although the exact role of this protein remains to be elucidated it has been shown to modulate exocytosis of neurotransmitters. Read about Brivaracetam

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
BRIVLERA Tablet, Oral solution, Solution for injection	Health Products and Food Branch (CA)	MPI, CA: SPM

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N03AX23		N Nervous system → N03 Antiepileptics → N03A Antiepileptics → N03AX Other antiepileptics
Discover more medicines within N03AX23

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 525220080024307, 525220080024407, 525220080024507, 525220080024607, 525220080024707, 525220080024807, 525220080024907, 525220080025007, 525220080025107, 525220080025207, 525220080025307, 525220080025407, 525220080025507, 525220080025607, 525220080025707
Country: CA	Health Products and Food Branch	Identifier(s): 02452936, 02452944, 02452952, 02452960, 02452979, 02452987, 02452995